12 Health Care Stocks Moving In Monday's Pre-Market Session

Benzinga · 03/24 12:10
Gainers
- Windtree Therapeutics (NASDAQ:WINT) stock increased by 39.2% to $2.06 during Monday's pre-market session. The market value of their outstanding shares is at $1.5 million.
- Allarity Therapeutics (NASDAQ:ALLR) shares moved upwards by 20.2% to $1.19. The market value of their outstanding shares is at $5.2 million.
- Capstone Holding (NASDAQ:CAPS) stock rose 19.18% to $2.05. The market value of their outstanding shares is at $2.8 million.
- Tharimmune (NASDAQ:THAR) shares rose 17.94% to $1.7. The market value of their outstanding shares is at $3.2 million.
- Regencell Bioscience (NASDAQ:RGC) shares increased by 17.7% to $69.01. The company's market cap stands at $898.0 million.
- ProPhase Labs (NASDAQ:PRPH) stock rose 16.54% to $0.36. The market value of their outstanding shares is at $10.8 million.
Losers
- 23andMe Holding (NASDAQ:ME) stock declined by 44.1% to $1.0 during Monday's pre-market session. The market value of their outstanding shares is at $26.8 million.
- Unity Biotechnology (NASDAQ:UBX) shares decreased by 37.0% to $1.15. The market value of their outstanding shares is at $19.3 million.
- TransCode Therapeutics (NASDAQ:RNAZ) shares decreased by 32.6% to $0.75.
- Impact BioMedical (AMEX:IBO) stock declined by 13.92% to $4.27. The market value of their outstanding shares is at $49.1 million.
- SunLink Health Systems (AMEX:SSY) shares decreased by 12.46% to $0.95. The market value of their outstanding shares is at $6.6 million.
- Helius Medical Tech (NASDAQ:HSDT) stock fell 10.89% to $0.38. The company's market cap stands at $1.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.